Innoquest Indonesia is part of Pathology Asia, the leading independent clinical diagnostics network in Southeast Asia (SEA). With a mission to provide high-quality, efficient, and actionable diagnostics, we serve hospitals, healthcare professionals, and patients with a commitment to excellence.
The visual identity of Innoquest represents the fusion of pathology and technology. By combining binary coding ('1s' and '0s') with bacterial cell structures seen under a microscope, we have developed a typeface that embodies the new DNA of Innoquest. This new identity symbolizes coordination, transformation, and the emergence of a pathology laboratory with a renewed vision.
"In pursuit of science, innovating for life."
The blue color spectrum represents trust, integrity, and credibility—ideal principles for a 21st-century healthcare company.
To improve patient outcomes by providing doctor with high quality, accessible and affordable clinical laboratory services, great customer service and innovative systems to support doctors, patients, and staff.
To become the leader in quality clinical laboratory services in Indonesia by striving for innovation in all areas of our business.
Making laboratory tests accessible to more people. With increased accessibility comes better affordability to larger groups of people, and more options for doctors to recommend lab tests for their patients
Innoquest’s presence spans across SEA, leading the clinical diagnostics industry with state-of-the-art technology and innovative solutions.
As a proud GDN partner, Innoquest collaborates with world-class laboratories, driving advancements in diagnostic science.
With nearly 30 years of expertise, Innoquest Indonesia is at the forefront of laboratory services, ensuring high-quality, accessible, and cost-effective medical diagnostics.
Innoquest Indonesia is redefining diagnostic excellence, integrating state-of-the-art technology, expert medical insights, and seamless patient care solutions to improve global healthcare outcomes.
Innoquest offers cutting-edge diagnostic solutions designed to provide precise and actionable health insights. Utilizing advanced technology, these tests enhance early disease detection, risk assessment, and personalized healthcare planning.
Non-Invasive. Accurate. Insightful.
Now available at Bali International Hospital
Take charge of your liver health with LiverSTAT — an advanced, non-invasive screening test designed to detect early signs of liver disease in individuals with metabolic risk factors.
LiverSTAT is a smart, AI-assisted blood test that uses just one blood draw to evaluate liver health, offering a quantitative fibrosis score and identifying fatty liver (steatosis) even in patients without advanced liver disease.
Ideal for individuals with:
Early detection is key. LiverSTAT helps you and your doctor take timely action to prevent serious liver conditions.
Decode Your Gut, Transform Your Health
Your gut is more than just a digestive system—it's the foundation of your overall wellness. The Amili Gut Microbiome Test offers a comprehensive analysis of your gut bacteria using Next Generation Sequencing (NGS) technology and a unique Asia-centric microbiome database.
A non-invasive stool sample test that maps the composition of your gut microbiota, delivering personalized insights into your health, diet, and disease risk.
Precision Oncology for Advanced & Metastatic Cancers
Take cancer diagnostics to the next level with OncoStrands™ Extended, a powerful DNA-based test designed to guide personalized cancer treatment through advanced molecular profiling.
Patients with advanced or metastatic cancer, especially those requiring MSI scoring to evaluate suitability for immunotherapy (checkpoint inhibitors) or needing precision treatment strategies based on genetic mutations.
A cutting-edge Next Generation Sequencing (NGS) assay that analyzes 109 key genes, including BRCA1/2 and DNA damage repair genes - Homologous Recombination Repair (HRR) genes, known to drive tumor development in:
This test is performed on FFPE tissue samples or cytology blocks, ensuring accurate results even from degraded samples.
Take a proactive step in understanding your genetic risk for cancer.
CancerNext® Expanded is a comprehensive hereditary cancer test that uses next-generation sequencing (NGS) technology to analyze 76 genes associated with an increased risk for a wide range of cancers, including:
This test is especially recommended for individuals with:
